Clinical trial
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
NCT00260039 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00260039 |
|---|---|
| Title | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) |
| Official title | A Randomized, International, Double-Blinded (With In-House Blinding), GARDASIL-Controlled, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine Administered to 16- to 23- Year-Old Women |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HPV, Cervical Cancer, Premalignancy Anogenital Warts |
| Intervention type | Biological |
| Interventions | Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2, Comparator: octavalent HPV Vaccine - dose formulation 3 |
| Enrollment | 680 |
| Start date | Dec 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Dec 1, 2005 |
| Last update posted | Jun 8, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: